SI

SillaJen, Inc.

Develops oncolytic viruses and immunotherapeutics to destroy difficult-to-treat cancer cells.

215600 | KO

Overview

Corporate Details

ISIN(s):
KR7215600008
LEI:
Country:
South Korea
Address:
서울특별시 중구 청계천로 106 3층(수표동, 크리스탈스퀘어), 중구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

SillaJen, Inc. is a biotechnology company focused on the research, development, and commercialization of oncolytic immunotherapeutics for cancer treatment. The company engineers oncolytic viruses designed to selectively replicate in and destroy cancer cells while stimulating a systemic anti-tumor immune response. Its main pipeline candidate is Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus that has been investigated for the treatment of various solid tumors. SillaJen is dedicated to developing innovative therapeutic options for patients with difficult-to-treat cancers through its proprietary viral engineering platforms.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-09 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획변경승인) (진행성 고형암 또는 재발성/불응성 급성 골수성 백혈병 환자를 대상으로 B…
Korean 28.0 KB
2025-08-14 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.9 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.6 MB
2025-08-05 00:00
Regulatory News Service
불성실공시법인지정 (공시변경)
Korean 6.1 KB
2025-07-15 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획변경승인신청) (진행성 고형암 또는 재발성/불응성 급성 골수성 백혈병 환자를 대상으로…
Korean 26.9 KB
2025-07-11 00:00
Regulatory News Service
불성실공시법인지정예고 (공시변경)
Korean 5.0 KB
2025-07-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-07-01 00:00
M&A Activity
합병등종료보고서(합병)
Korean 16.7 KB
2025-06-23 00:00
M&A Activity
합병등종료보고서(자산양수도)
Korean 16.5 KB
2025-06-19 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획변경승인신청) (진행성 고형암 또는 재발성/불응성 급성 골수성 백혈병 환자를 대상으로…
Korean 26.2 KB
2025-06-13 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획변경승인) (진행성 고형암 또는 재발성/불응성 급성 골수성 백혈병 환자를 대상으로 B…
Korean 25.5 KB
2025-05-29 00:00
Post-Annual General Meeting Information
기타경영사항(자율공시) (소규모 합병 승인 이사회 결의(주주총회 갈음) 결과 보고)
Korean 8.0 KB
2025-05-29 00:00
M&A Activity
[기재정정]주요사항보고서(타법인주식및출자증권양도결정)
Korean 40.6 KB
2025-05-29 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 57.3 KB
2025-05-29 00:00
Remuneration Information
[기재정정]주식매수선택권부여에관한신고
Korean 31.3 KB

Automate Your Workflow. Get a real-time feed of all SillaJen, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SillaJen, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SillaJen, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Whitehawk Therapeutics, Inc. Logo
Develops advanced antibody-drug conjugates (ADCs) for difficult-to-treat cancers.
United States of America
WHWK
WooGeneB&GCO.,Ltd Logo
Manufactures veterinary medicines, vaccines, and supplements for livestock and aquatic animals.
South Korea
018620
X4 Pharmaceuticals, Inc Logo
Developing and commercializing novel therapies for rare diseases of the immune system.
United States of America
XFOR
XBiotech Inc. Logo
Develops therapeutic antibodies from natural human immunity for inflammatory diseases and oncology.
United States of America
XBIT
Xbrane Biopharma Logo
Develops affordable biosimilars for serious diseases using patented, high-yield production tech.
Sweden
XBRANE
Xencor Inc Logo
Engineering antibody & cytokine therapeutics for cancer and autoimmune diseases via its XmAb platform.
United States of America
XNCR
Xenon Pharmaceuticals Inc. Logo
A neuroscience biopharma developing novel therapeutics for epilepsy and depression.
United States of America
XENE
Xeris Biopharma Holdings, Inc. Logo
Develops ready-to-use injectable drugs for chronic, metabolic, and rare diseases.
United States of America
XERS
Xintela AB Logo
Develops stem cell therapies for osteoarthritis and venous leg ulcers using proprietary technology.
Sweden
XINT
Xspray Pharma Logo
Develops improved cancer drugs (PKIs) using patented tech to circumvent secondary patents.
Sweden
XSPRAY

Talk to a Data Expert

Have a question? We'll get back to you promptly.